SeaStar Medical Expands Market Reach with QUELIMMUNE Sales Growth and Adult AKI Trial Progress

Medical device company SeaStar Medical demonstrated substantial commercial progress in its first quarter of 2025, with QUELIMMUNE sales increasing fourfold and strategic expansion into the adult acute kidney injury (AKI) market underway.

The company's flagship product, QUELIMMUNE, received FDA approval under a Humanitarian Device Exemption for treating pediatric AKI caused by sepsis. First quarter net product revenue reached $293,000, compared to $67,500 in the previous quarter, signaling growing market adoption among pediatric healthcare providers.

SeaStar is now setting its sights on the significantly larger adult AKI market, which represents an estimated $4.5 billion annual opportunity. The company's NEUTRALIZE-AKI pivotal trial, evaluating its Selective Cytopheretic Device (SCD) therapy in adult patients, has reached 50% enrollment. If successful, SeaStar anticipates filing for adult market approval in 2026.

The SCD therapy's innovative approach neutralizes destructive hyperinflammatory cells that can cause organ failure in critically ill patients. This technology underpins QUELIMMUNE and represents a potential breakthrough in managing life-threatening kidney complications.

CEO Eric Schlorff highlighted the company's commitment to expanding its therapeutic reach, noting ongoing engagement with physicians and healthcare providers to educate them about the potential of SCD therapy. The company also received two additional Breakthrough Device Designations, bringing its total to six therapeutic indications.

Financial performance showed promising signs, with the company's net loss narrowing to $3.8 million in the first quarter, compared to $12.7 million in the same period last year. Cash reserves increased to $5.3 million, supported by a $6 million registered direct offering.

As SeaStar Medical continues to advance its clinical trials and commercial strategy, the company remains focused on its mission of transforming treatments for critically ill patients facing organ failure, with potential life-saving implications for both pediatric and adult patient populations.